|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Schwannomatosis/Multiple Schwannoma Panel (SCH-NG)
Test Code11549
CPT Codes
81405, 81406, 81479<br><strong>This test is not available for New York patient testing.</strong><br>Limited Access Code
Preferred Specimen
6 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
3 mL
Other Acceptable Specimens
Saliva collected in OGR-575 DNA Genotek (kits are provided upon request) • DNA (extracted from lymphocyte cells; a minimum volume of 25 uL at 3 ug; O.D. of 260:280nm ≥ 1:8; must be extracted in a CLIA or equivalent certified lab)) • Flash frozen tumor sent on dry ice • Fresh tumor or affected tissue biopsy, immersed in sterile culture media (PBS/RPMI)
Transport Temperature
Room temperature
Specimen Stability
Not established
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
No label (patient's full name and date of collection) on the specimens • No referring physician's or genetic counselor's names and addresses • No billing information • DNA samples must be extracted in a CLIA or equivalent certified lab
Methodology
Next Generation Sequencing
FDA Status
This test was developed and its performance characteristics determined by the Medical Genomics Laboratory. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is use for clinical purposes. It should not be regarded as investigational or for research.
Setup Schedule
Set up: Varies; Report available: 30 working days
Reference Range
See Laboratory Report
Clinical Significance
Patients with multiple schwannomas with or without vestibular schwannomas. This testing approach is developed to diagnose mosaic NF2, classic NF2, Schwannomatosis, and mosaic schwannomatosis.
